Bristol-Myers Squibb has teamed up with Johns Hopkins University to research why patients respond and develop resistance to its PD-1 drug Opdivo.

Bristol-Myers Squibb has teamed with Infinity Pharmaceuticals to add another study to its burgeoning roster of combination trials featuring PD-1 drug Opdivo.

The IPO raised the offer price and the number of shares sold with backing from new investors Pfizer and BB Biotech.

An IPO for Ra Pharmaceuticals has priced raising $92 million, while another for Myovant Sciences has commitments from Pfizer and BB Biotech.

Merck is confident that its Keytruda will work well in combination with traditional chemotherapy. Up next are next-gen combos.

NantVentures has made an investment in microcap Australian biotech Benitec Biopharma.

NeuroVive Pharmaceutical has resolved its standoff with Arbutus Biopharma and regained control of a hepatitis B candidate.

Novartis teed up its second discovery deal of the day with an investment and partnership with Perlara PBC to discover and develop treatments for lysosomal…

Partnering